Onesource Specialty Pharma Limited
Mirae Asset Mutual Fund reduced its stake in Onesource Specialty Pharma Limited from 1.22% to 1.13%, selling 1,07,749 shares.
A specialist pharmaceutical company engaged in the research, development, and manufacturing of biological drug products in injectable formats for therapeutic use. OneSource Specialty Pharma provides comprehensive contract development and manufacturing organization services spanning all phases of preclinical and clinical development, alongside commercial supply of biologics to domestic and international pharmaceutical clients and healthcare providers.
Indian arm of South Korea's Mirae Asset Global Investments, one of Asia's largest asset managers. Manages over Rs 2.5 lakh crore in India across equity and hybrid funds. CIO Neelesh Surana has built a reputation for rigorous bottom-up stock selection with a long-term quality growth bias. Mirae Asset Emerging Bluechip Fund built a cult following before being closed to fresh investments due to size.